Inclusion Criteria:

• Post-menopausal females, in good health and between 40 and 65 years of age.
• Normal body mass index equal or greater than 18 but not greater than 36
• Postmenopausal as defined by 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 30 mlU/ml or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, or hysterectomy with FSH levels > 30 mlU/ml.
• Ability to comprehend and a willingness to sign an informed consent form.
• Ability and willingness to understand and follow study procedures.
• Clinical laboratory evaluations within the reference range for the testing laboratory, unless regarded not clinically significant by the Principle Investigator.
• Must have had mammogram within the last 9 months.
• Negative urine test for selected drugs of abuse at screening and after check-in at the study unit.
• Negative hepatitis panel (including HBsAg and anti-HCV), and HIV antibody screens.
• No chronic medications being taken.
• Must have a primary care physician.

Exclusion Criteria:

• History or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, hepatic, gall bladder, renal, urological, or psychiatric disorders.
• Dyslipidemia
• History of abnormal renal function, uncontrolled hypertension, or malignancies.
• History of breast, uterine or ovarian cancer or melanoma.
• History of brain aneurism or ischemic events.
• Febrile disease
• Autoimmune disorders such as lupus erythematosis, multiple sclerosis or rheumatoid arthritis.
• Severe vasomotor symptoms defined as > 7/day or >50/week.
• Abnormal mammogram or breast examination within the last 9 months suggestive of cancer.
• Abnormal Pap smear or pelvic examination within the last 9 months suggestive of cancer.
• Double-wall endometrial thickness that exceeds 5 mm measured on transvaginal ultrasound.
• Unexplained abnormal uterine bleeding within six months of enrollment.
• Pregnancy or lactating.
• History of deep vein thrombosis or pulmonary embolism requiring anticoagulation.
• History of hypersensitivity or allergies to any drug compound, including the constituents of MF101 unless approved by the Principle Investigator.
• History or presence of a clinically significant abnormal ECG (QTcB > 450msec at screening or variation in QTcB > 30msec at screening).
• Likely to need medication during the study including contraceptives.
• History of alcoholism or drug addiction within 1 year prior to study entry (i.e., prior to check-in on Day-1).
• Use of any tobacco products (including cigarette, pipe, cigar, chewing, nicotine patch, or nicotine gum) within 6 months prior to study entry.
• Receipt of any investigational drug within 60 days prior to study entry.
• Use of prescription medications known to possibly be effective for the treatment of hot flashes within three months of enrollment for oral or transdermal drugs, or within 6 months of enrollment for implanted or injected drugs.
• Use of raloxifene, tamoxifen or aromatase inhibitors within three months of enrollment.
• Use of any other prescription medication or any alcohol-containing products/medications within 14 days prior to study entry.
• Use of over-the-counter, non-prescription preparations, within 7 days prior to study entry.
• Use of any caffeine-containing products/medications within 72 hours prior to study entry.
• Donation of blood within 6 weeks prior to study entry or of plasma within 2 weeks prior to screening.
• Receipt of blood products within 2 months prior to study entry.
• Any other condition or prior therapy which, in the opinion of the Investigator, would make the subject unsuitable for this study.